Pitofsky Jason

SVP Controller Pitofsky sold 2,036 shares of REGN for $1.6M in 11 transactions on 2026-02-09

Jason Pitofsky, SVP Controller at Regeneron Pharmaceuticals, executed 11 separate sales totaling 2,036 shares for $1,585,058.14 on 2026-02-09, reducing his holdings from 6,308 shares to 4,272 shares (-32.3%). The blended average price across these transactions was $778.52, within the stock's recent trading range and just 4.1% below the 52-week high of $812.27. His prior sell transaction at REGN (2024-08-07) posted a 90-day return of -22.5%, representing 1 of 1 prior sells as well-timed at the 90-day mark. The company fundamentals show solid profitability (net income $1.5B on revenue $3.8B) with modest annual revenue growth of +1.0% and a P/E of 15.67, providing no obvious red flag context for the sale. Without knowledge of whether this sale is scheduled under a 10b5-1 plan or discretionary, the stock's recent 90-day uptrend (+12.1%) and prior sale timing pattern merit investor monitoring.

VP Controller Jason Pitofsky sells 487 REGN shares at $1,070.00; holds 4.2K shares post-sale

Jason Pitofsky, VP Controller of Regeneron Pharmaceuticals, sold 487 shares at $1,070.00 for $521,090.00 on 2024-08-07, reducing his holdings from 4.7K to 4.2K shares (a -10.4% reduction in position size). The sale occurred near the upper end of the 52-week range ($766.44–$1100.05), specifically 2.9% below the 52-week high, at a price that exceeds the current market price of $1,067.80 by $2.20 per share. The timing and price level alone do not indicate directional confidence; the stock has posted a +1.5% gain over the prior 30 days and +10.3% over the prior 90 days, reflecting positive momentum. Without a trading plan flag or track record specific to REGN transactions, this represents a discretionary open-market sale by a CFO-level finance executive at a price approaching recent highs.